Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: ACC-001 Clinical Trials Are Ongoing

(2017) J. Michael Ryan et al.   JOURNAL OF ALZHEIMERS DISEASE

2013 Alzheimer's disease facts and figures

(2013)   Alzheimers & Dementia

Immunotherapy in Alzheimer’s Disease: Do We Have All the Pieces of the Puzzle?

(2013) Marie Sarazin et al.   BIOLOGICAL PSYCHIATRY

CR1 and the “Vanishing Amyloid” Hypothesis of Alzheimer’s Disease

(2013) Sam Gandy et al.   BIOLOGICAL PSYCHIATRY

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

(2013) Aaron H. Burstein et al.   CLINICAL NEUROPHARMACOLOGY

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies

(2013) Hanna Rosenmann   Current Alzheimer Research

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

(2013) Lea Rozenstein-Tsalkovich et al.   EXPERIMENTAL NEUROLOGY

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?

(2013) Haythum O Tayeb et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?

(2013) Yun Li et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Intravenous immunoglobulin and Alzheimer’s disease: what now?

(2013) David A Loeffler   Journal of Neuroinflammation

Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial

(2013) H. Davtyan et al.   JOURNAL OF NEUROSCIENCE

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta

(2013) Ana Griciuc et al.   NEURON

Development of a New DNA Vaccine for Alzheimer Disease Targeting a Wide Range of Aβ Species and Amyloidogenic Peptides

(2013) Yoh Matsumoto et al.   PLoS One

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype

(2012) Madhav Thambisetty et al.   BIOLOGICAL PSYCHIATRY

AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease

(2012) Uwe Konietzko   Current Alzheimer Research

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

(2012) Nadege Zommer et al.   Current Alzheimer Research

Gantenerumab for the treatment of Alzheimer's disease

(2012) Julien Delrieu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

New and emerging treatments for Alzheimer’s disease

(2012) Anne Corbett et al.   Expert Review of Neurotherapeutics

Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

(2012) Francesco Panza et al.   Immunotherapy

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

(2012) Jungsu Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice

(2012) Yu Li et al.   JOURNAL OF NEUROIMMUNOLOGY

Therapeutic strategies for tau mediated neurodegeneration

(2012) Y. Yoshiyama et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice

(2012) A C Santuccione et al.   MOLECULAR PSYCHIATRY

Genentech's Alzheimer's antibody trial to study disease prevention

(2012) Ken Garber   NATURE BIOTECHNOLOGY

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model

(2012) Jose Morales-Corraliza et al.   NEUROBIOLOGY OF AGING

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variant TREM2 as Risk Factor for Alzheimer's Disease

(2012) Harald Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stopping Alzheimer's Before It Starts

(2012) G. Miller   SCIENCE

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Nuclear signalling by membrane protein intracellular domains: The AICD enigma

(2011) Caroline Beckett et al.   CELLULAR SIGNALLING

Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

(2011) Francesco Panza et al.   Current Alzheimer Research

Antibody-based therapy in Alzheimer's disease

(2011) Refik Pul et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

The physiology of the β-amyloid precursor protein intracellular domain AICD

(2011) Raphaëlle Pardossi-Piquard et al.   JOURNAL OF NEUROCHEMISTRY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

(2011) Mian Bi et al.   PLoS One

Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model

(2011) Jun Nojima et al.   VACCINE

The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia

(2010) Jessica M. Mc Donald et al.   BRAIN

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

TAU Aggregation is a Therapeutic Target for Alzheimers Disease

(2010) A. Takashima   Current Alzheimer Research

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

(2010) Moran Boimel et al.   EXPERIMENTAL NEUROLOGY

The Transcriptionally Active Amyloid Precursor Protein (APP) Intracellular Domain Is Preferentially Produced from the 695 Isoform of APP in a β-Secretase-dependent Pathway

(2010) Nikolai D. Belyaev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

(2010) Johanna Magga et al.   Journal of Neuroinflammation

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

β-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain

(2010) Erica Buoso et al.   PHARMACOLOGICAL RESEARCH

APP Intracellular Domain Impairs Adult Neurogenesis in Transgenic Mice by Inducing Neuroinflammation

(2010) Kaushik Ghosal et al.   PLoS One

Decreased Clearance of CNS  -Amyloid in Alzheimer's Disease

(2010) K. G. Mawuenyega et al.   SCIENCE

Mechanisms of tau-induced neurodegeneration

(2009) Khalid Iqbal et al.   ACTA NEUROPATHOLOGICA

Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy

(2009) Michal Novak   Alzheimers & Dementia

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease

(2009) Francesco Panza et al.   DRUGS & AGING

Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway

(2009) Z. V. Goodger et al.   JOURNAL OF CELL SCIENCE

Vaccination with A -Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A  and Lowers Plaque Burden in APP Transgenic Mice

(2009) P. Bach et al.   JOURNAL OF IMMUNOLOGY

A  Immunotherapy: Intracerebral Sequestration of A  by an Anti-A  Monoclonal Antibody 266 with High Affinity to Soluble A 

(2009) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

(2009) Kurt R. Brunden et al.   NATURE REVIEWS DRUG DISCOVERY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain

(2009) K. Ghosal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotype

(2008) Nina Movsesyan et al.   JOURNAL OF NEUROIMMUNOLOGY

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse

(2008) Peter Seubert et al.   Neurodegenerative Diseases

Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy

(2008) Nina Movsesyan et al.   PLoS One

The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics—Relevance for Alzheimer's disease

(2008) Thorsten Müller et al.   PROGRESS IN NEUROBIOLOGY